Notal Vision is set to launch its second product, home-based optical coherence tomography (OTC) for monitoring of retinal fluid accumulation in patients with retinal disease, chief medical office and vice president, medical affairs, Susan Orr, reported at the Company Showcase 3 session at OIS@AAO 2017. Home OCT utilizes spectral-domain technology and is reimbursable, Orr said. Results upload to the cloud for review by an independent diagnostic testing center that alerts physicians when retinal fluid becomes problematic. Orr noted that Notal Vision is the only ophthalmology company with a Medicare-established reimbursement model for an independent diagnostic testing facility. Notal Vision already has an approved platform for home monitoring of wet age-related macular degeneration with its ForeseeHome system.